CMS

China Medical System Holdings (CMS; HKG: 0867) has entered into a licensing agreement with Shanghai-based Baiyiyuan Biotech, securing exclusive rights to promote, market, and commercialize Baiyiyuan’s decellularized matrix implant across Greater China, including the China mainland, Hong Kong, Macau, and Taiwan. The financial details of the agreement were not disclosed.…